On 1 October 2024, Johnson & Johnson (J&J) announced a $2b investment in a new, advanced technology biologics manufacturing facility in North Carolina. J&J states that the new facility will expand production of the company’s biologics portfolio and pipeline as part of a broader plan to advance more than 70 novel therapy and product expansion filings and launches by 2030. Construction is anticipated to commence in the first half of 2025.
J&J has received a number of FDA new indication approvals this year, including, Rybrevant® (amivantamab-vmjw) in combination with standard of care chemotherapy (carboplatin and pemetrexed) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) (September 2024), Tremfya® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (September 2024), and Darzalex Faspro® (daratumumab and hyaluronidase) for Multiple Myeloma (July 2024).